OpGen (NASDAQ:OPGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN) in a research report sent to investors on Wednesday. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Trading Down 3.1 %

OPGN opened at $0.47 on Wednesday. The company has a market capitalization of $5.93 million, a price-to-earnings ratio of -0.07 and a beta of -0.56. OpGen has a 12-month low of $0.17 and a 12-month high of $3.84. The business’s fifty day simple moving average is $0.57 and its 200-day simple moving average is $0.50.

Institutional Investors Weigh In On OpGen

A hedge fund recently bought a new stake in OpGen stock. Chase Investment Counsel Corp acquired a new position in OpGen, Inc. (NASDAQ:OPGN) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned approximately 2.63% of OpGen as of its most recent SEC filing. Institutional investors and hedge funds own 2.68% of the company’s stock.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.